• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
GYN
CMECNE

Pregnancy of Unknown Location – Next Steps

image_pdfFavoriteLoadingFavorite

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. Define ‘a pregnancy of unknown location’
2. Discuss the use of uterine aspiration in the setting of a pregnancy of unknown location

Estimated time to complete activity: 0.25 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG
President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose. The OBG Project planners and others have nothing to disclose.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from March 12 2018 through 07/15/2022, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.2 contact hours.

Designated for 0.1 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Read Disclaimer & Fine Print

SUMMARY:

Pregnancy of unknown location is defined as a pregnancy where intrauterine or ectopic location cannot be confirmed. If the location cannot be definitively determined

  • Pregnancy of unknown location requires follow up and a diagnosis
  • If patient is clinically stable and pregnancy is desired
    • Repeat transvaginal ultrasound and/or serial measurement of hCG

Uterine Aspiration to Determine Pregnancy Location

Perform uterine aspiration if pregnancy is not progressing normally (see ‘Related ObG Topics’ below)

  • Chorionic villi present
    • Indicates failed uterine pregnancy
    • No further follow-up needed
  • Chorionic villi absent
    • Monitor hCG levels 12–24 hours after aspiration
    • hCG plateau (decrease <10-15%) indicates the following possible scenarios
      • Uterine evacuation incomplete
      • Ectopic pregnancy, but not seen on ultrasound
    • hCG decrease ≥50%
      • Monitor with serial hCG measurements
      • Treat if patient becomes symptomatic or levels plateau or increase
    • hCG decrease between 15% and 50%
      • Individualize treatment
      • Follow-up with serial hCG measurements
      • Treat if (1) patient becomes symptomatic, (2) levels plateau or increase, (3) there is clinical suspicion or (4) strong risk factors for ectopic pregnancy are present

Determination of Pregnancy Location Prior to Methotrexate (MTX) Use

  • Arguments against determining location prior to MTX
    • Delay in MTX treatment may result in a potentially preventable tubal rupture
  • Arguments for determining location prior to MTX
    • Limits MTX exposure to those patients who actually need it
    • Confirmation/knowledge of true location may impact management of current and future pregnancies
    • Risk of rupture appears to be low if patient is closely monitored

KEY POINTS:

  • Choice of uterine aspiration should be based on shared decision making
    • Discuss risk of MTX and birth defects if location not confirmed and intrauterine pregnancy continues
  • Consider MTX if following met
    • Confirmed or high clinical suspicion of ectopic pregnancy
    • Hemodynamically stable
    • Unruptured mass
    • No absolute contraindications to MTX
  • Absolute MTX Contraindications include
    • Intrauterine Pregnancy | Breastfeeding | Immunodeficiency | Blood Dyscrasias | Clinically Important Hepatic Dusfunction | Active Pulmonary Disease | Active Peptic Ulcer Disease | Clinically Important Renal Dysfunction | Patient sensitive to MTX | Inability to Participate in Follow-up
  • Relative MTX Contraindications
    • Gestational Sac > 4 cm (TV ultrasound) | High Quantitative HCG (qHCG) | Positive FH | Refusal to Accept Blood Transfusion

Learn More – Primary Sources:

ACOG Practice Bulletin 193: Tubal Ectopic Pregnancy  

Practice Committee of American Society for Reproductive Medicine. Medical treatment of ectopic pregnancy: a committee opinion. 

Diagnosing ectopic pregnancy and current concepts in the management of pregnancy of unknown location 

Take a post-test and get CME credits

TAKE THE POST TEST

Get Guideline Notifications Direct to Your Phone

ObGFirst® – Try It Free! >>

image_pdfFavoriteLoadingFavorite

< Previous
All GYN Posts
Next >

Related ObG Topics:

Diagnosing the Extrauterine Pregnancy-What You Need to Know
You’ve Diagnosed the Ectopic Pregnancy – When and How to Use the Medical Option
Ectopic Pregnancy: Expectant Management vs. Methotrexate?
Ectopic Pregnancy Methotrexate Protocol: Single-Dose or 2-Dose?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site